Education
About Us
Working with TipRanks
Follow Us
TherapeuticsMD (TXMD)
NASDAQ:TXMD
Top Page
TherapeuticsMD
(NASDAQ:TXMD)
33Underperform
TherapeuticsMD (TXMD) vs. S&P 500 (SPY)
Market Cap
$9.23M
Dividend YieldN/A
Average Volume (3M)551.87K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1
SectorHealthcare
Sector Strength78
IndustryPharmaceuticals
Share Statistics
EPS (TTM)-0.29
Shares Outstanding11,532,432
10 Day Avg. Volume103,934
30 Day Avg. Volume551,872
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.92
Price to Cash Flow (P/CF)-123.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
TherapeuticsMD Business Overview & Revenue Model
Company DescriptionTherapeuticsMD, Inc. (TXMD) is a healthcare company focused on developing and commercializing innovative products for women. Operating primarily in the pharmaceutical sector, the company's core products include hormone therapy solutions aimed at addressing various aspects of women's health, such as menopause and contraception. TherapeuticsMD is dedicated to enhancing the quality of life for women through its distinctive formulations and delivery platforms.
How the Company Makes MoneyTherapeuticsMD generates revenue through the sale of its proprietary pharmaceutical products. The company's revenue model is based on the commercialization of its FDA-approved therapies, which are distributed through a network of healthcare providers, pharmacies, and wholesalers. Key revenue streams include sales of its hormone therapy products, such as BIJUVA and IMVEXXY, which are designed to treat menopause symptoms, and ANNOVERA, a contraceptive product. TherapeuticsMD may also engage in strategic partnerships, licensing agreements, or collaborations to further expand its market reach and product offerings, thus contributing to its earnings.
TherapeuticsMD Financial Statement Overview
Summary
TherapeuticsMD is facing significant financial challenges, with declining revenues and high losses impacting profitability. The balance sheet shows high leverage, although some improvements in debt levels are noted. Persistent negative cash flows raise concerns about liquidity and financial sustainability in the near term.Income Statement
TherapeuticsMD shows a significant decline in revenue and profitability metrics. The TTM data indicates negative EBIT and EBITDA margins, with a substantial net loss, which is concerning. Revenue growth has also been negative, indicating a challenging business environment.20
Very Negative
Balance Sheet
The balance sheet reflects a high debt-to-equity ratio, although it has improved over the years. The company has reduced liabilities, but equity remains low. The equity ratio is weak, suggesting financial instability and a high-risk profile.30
Negative
Cash Flow
Cash flow metrics are troubling, with a persistent negative operating cash flow. The company has been unable to generate positive free cash flow, and the free cash flow to net income ratio is unfavorable. This indicates liquidity issues which could impact future operations.15
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.60M | 1.30M | 69.96M | 86.95M | 64.87M | 49.65M | Gross Profit |
| 826.00K | 1.30M | 68.57M | 68.11M | 48.90M | 43.31M | EBIT |
| -6.05M | -8.52M | 20.14M | -139.77M | -155.54M | -151.21M | EBITDA |
| -2.88M | -8.40M | 11.86M | -78.57M | -149.47M | -156.31M | Net Income Common Stockholders |
| -3.32M | -10.28M | 112.00M | -205.60M | -212.70M | -196.03M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 161.61M | 4.33M | 38.07M | 65.12M | 80.49M | 160.83M | Total Assets |
| 211.98M | 43.31M | 90.46M | 169.47M | 181.61M | 265.99M | Total Debt |
| 73.38M | 8.01M | 8.76M | 196.33M | 246.37M | 203.78M | Net Debt |
| -88.23M | 3.68M | -29.31M | 131.21M | 165.89M | 42.95M | Total Liabilities |
| 114.46M | 14.02M | 55.31M | 263.09M | 305.61M | 256.78M | Stockholders Equity |
| 97.52M | 29.29M | 35.14M | -93.62M | -124.00M | 9.20M |
| Cash Flow | Free Cash Flow | ||||
| -7.01M | -48.14M | -4.43M | -144.92M | -161.07M | -189.59M | Operating Cash Flow |
| -7.01M | -48.14M | -4.08M | -142.69M | -159.47M | -165.70M | Investing Cash Flow |
| 0.00 | 0.00 | 223.48M | -2.22M | -1.60M | -23.91M | Financing Cash Flow |
| 2.00M | 3.15M | -235.21M | 129.55M | 80.72M | 188.83M |
TherapeuticsMD Technical Analysis
Negative
0.76
Price Trends
1.04
Negative
1.22
Negative
1.51
Negative
Market Momentum
-0.07
Positive
35.03
Neutral
25.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.04, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 35.03 is Neutral, neither overbought nor oversold. The STOCH value of 25.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXMD.
TherapeuticsMD Risk Analysis
TherapeuticsMD disclosed 45 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TherapeuticsMD Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $1.34B | ― | -4.86% | ― | 26.20% | -219.22% | |
53 Neutral | $806.28M | ― | -913.07% | ― | 31.76% | 24.85% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
48 Neutral | $73.80M | ― | -42.36% | ― | -25.77% | 51.98% | |
36 Underperform | $19.92M | ― | 422.38% | ― | -95.07% | 40.41% | |
34 Underperform | $58.70M | ― | -2059.89% | ― | 187.45% | -69.90% | |
33 Underperform | $9.23M | ― | -14.39% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
TXMD
TherapeuticsMD
0.76
-1.62
-68.07%
ASRT
Assertio Therapeutics
0.77
-0.37
-32.46%
PTN
Palatin Technologies
0.77
-0.83
-51.88%
ANIP
ANI Pharmaceuticals
63.26
-2.97
-4.48%
EOLS
Evolus
12.71
-1.33
-9.47%
VRCA
Verrica Pharmaceuticals
0.60
-4.56
-88.37%
TherapeuticsMD Corporate Events
M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
TherapeuticsMD Shifts Focus with Lower Q3 Losses
Neutral
Nov 12, 2024
TherapeuticsMD, Inc. reported a reduced net loss for Q3 2024, with operating expenses also declining due to its shift to a royalty-based business model. The company is exploring strategic alternatives, including potential mergers or acquisitions, but has not committed to any specific actions. Their cash reserves stand at $5 million, as they continue to focus on maximizing shareholder value amid a volatile stock environment.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.